Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

FOR years, Emma Morris hid from cameras, avoided mirrors and felt like a prisoner in her own body because of her weight. But ...

Eli Lilly shares fell after the company’s oral drug showed less weight loss than hoped. It could still be huge.

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly “bribing” providers to prescribe its ...

To make things a little less confusing, we’re here with all the info you need about popular weight loss med Mounjaro.

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.

Doctors suggest that anybody with a Body mass index of over 30 or greater than 27 is advised to try weight loss drugs.

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...